1. Home
  2. RVMDW
  3. RVMDW News

Latest Revolution Medicines Inc. Warrant (RVMDW) News on December 23, 2024

One Revolution Medicines Insider Raised Their Stake In The Previous Year
RVMDW

Simply Wall St.

11 days ago

One Revolution Medicines Insider Raised Their Stake In The Previous Year

RVMDW

MT Newswires

16 days ago

Wedbush Cuts Price Target on Revolution Medicines to $67 From $70, Keeps Outperform Rating

RVMDW

MT Newswires

17 days ago

Revolution Medicines Closes Offering of 16.6 Million Shares

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
RVMDW

GlobeNewswire

17 days ago

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines price target raised to $87 from $82 at Guggenheim
RVMDW

TipRanks

19 days ago

Revolution Medicines price target raised to $87 from $82 at Guggenheim

RVMDW

MT Newswires

19 days ago

Revolution Medicines Prices $45 Million Stock, Warrant Offering

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
RVMDW

GlobeNewswire

19 days ago

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

RVMDW

MT Newswires

20 days ago

Revolution Medicines Launches $600 Million Offering of Common Shares

Revolution Medicines Announces Commencement of Public Offering of Common Stock
RVMDW

GlobeNewswire

20 days ago

Revolution Medicines Announces Commencement of Public Offering of Common Stock

RVMDW

MT Newswires

20 days ago

Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating

RVMDW

MT Newswires

20 days ago

Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
RVMDW

GlobeNewswire

21 days ago

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
RVMDW

GlobeNewswire

25 days ago

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight
RVMDW

GuruFocus.com

a month ago

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight

RVMDW

MT Newswires

2 months ago

Revolution Medicines Q3 Loss Narrows; Reaffirms Full-Year Guidance

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
RVMDW

GuruFocus.com

2 months ago

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
RVMDW

GlobeNewswire

2 months ago

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

RVMDW

MT Newswires

2 months ago

Revolution Medicines Insider Sold Shares Worth $3,878,773, According to a Recent SEC Filing

Revolution Medicines to Participate in Upcoming Investor Conferences
RVMDW

GlobeNewswire

2 months ago

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For
RVMDW

GuruFocus.com

2 months ago

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
RVMDW

GlobeNewswire

2 months ago

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

RVMDW

MT Newswires

2 months ago

Revolution Medicines Says Potential Pancreatic Cancer Treatment Shows 'Encouraging' Initial Results

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
RVMDW

GlobeNewswire

2 months ago

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
RVMDW

GlobeNewswire

2 months ago

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

RVMDW

MT Newswires

2 months ago

Revolution Medicines Doses First Patient in Phase 3 Study of Pancreatic Cancer Drug

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
RVMDW

GlobeNewswire

2 months ago

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

RVMDW

MT Newswires

2 months ago

Revolution Medicines Insider Sold Shares Worth $824,804, According to a Recent SEC Filing

RVMDW

MT Newswires

2 months ago

Revolution Medicines Insider Sold Shares Worth $1,510,773, According to a Recent SEC Filing

RVMDW

MT Newswires

2 months ago

Revolution Medicines Insider Sold Shares Worth $2,517,055, According to a Recent SEC Filing

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
RVMDW

GlobeNewswire

3 months ago

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

RVMDW

MT Newswires

3 months ago

Revolution Medicines Insider Sold Shares Worth $517,631, According to a Recent SEC Filing

RVMDW

MT Newswires

3 months ago

89bio Appoints Teresa Perney as Chief Regulatory, Quality Officer

Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks
RVMDW

Insider Monkey

3 months ago

Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks

RVMDW

MT Newswires

4 months ago

Revolution Medicines Insider Sold Shares Worth $716,389, According to a Recent SEC Filing

Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)
RVMDW

Simply Wall St.

4 months ago

Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)

RVMDW

Thomson Reuters StreetEvents

4 months ago

Q2 2024 Revolution Medicines Inc Earnings Call

RVMDW

MT Newswires

4 months ago

Revolution Medicines Q2 Loss Narrows

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
RVMDW

GlobeNewswire

4 months ago

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

RVMDW

MT Newswires

5 months ago

Revolution Medicines Insider Sold Shares Worth $458,827, According to a Recent SEC Filing

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
RVMDW

Zacks

5 months ago

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
RVMDW

GlobeNewswire

5 months ago

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

RVMDW

MT Newswires

5 months ago

Barclays Adjusts Price Target on Revolution Medicines to $54 From $52, Maintains Overweight Rating

RVMDW

MT Newswires

5 months ago

UBS Adjusts Price Target on Revolution Medicines to $65 From $40, Maintains Buy Rating

RVMDW

MT Newswires

5 months ago

Revolution Medicines Insider Sold Shares Worth $1,576,322, According to a Recent SEC Filing

RVMDW

MT Newswires

5 months ago

Needham Adjusts Revolution Medicines Price Target to $62 From $46, Maintains Buy Rating

RVMDW

MT Newswires

5 months ago

HC Wainwright Raises Price Target on Revolution Medicines to $56 From $44, Maintains Buy Rating

RVMDW

MT Newswires

5 months ago

Oppenheimer Adjusts Revolution Medicines Price Target to $55 From $45, Maintains Outperform Rating

RVMDW

MT Newswires

5 months ago

Revolution Medicines Projects 2024 Net Loss of $560 Million to $600 Million; Provides Latest Cancer Drug Study Data

RVMDW

MT Newswires

5 months ago

Wedbush Raises Price Target on Revolution Medicines to $59 From $46, Maintains Outperform Rating

Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
RVMDW

BioPharma Dive

5 months ago

Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data

RVMDW

MT Newswires

5 months ago

Barclays Initiates Revolution Medicines at Overweight With $52 Price Target

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
RVMDW

GlobeNewswire

5 months ago

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
RVMDW

Zacks

5 months ago

Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
RVMDW

GlobeNewswire

5 months ago

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

RVMDW

MT Newswires

5 months ago

Jefferies Initiates Revolution Medicines at Buy With $63 Price Target

Insider Sale: COO Margaret Horn Sells Shares of Revolution Medicines Inc (RVMD)
RVMDW

GuruFocus.com

6 months ago

Insider Sale: COO Margaret Horn Sells Shares of Revolution Medicines Inc (RVMD)

RVMDW

MT Newswires

6 months ago

Revolution Medicines Insider Sold Shares Worth $446,770, According to a Recent SEC Filing

Shareholders Will Most Likely Find Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Acceptable
RVMDW

Simply Wall St.

6 months ago

Shareholders Will Most Likely Find Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Acceptable

Edge Total Intelligence Inc. Updates Status of MCTO
RVMDW

Newsfile

6 months ago

Edge Total Intelligence Inc. Updates Status of MCTO

Fortegra Granted License to Operate in Belgium and European Union
RVMDW

PR Newswire

6 months ago

Fortegra Granted License to Operate in Belgium and European Union

Jamaica Villas Offers "Free Driver" Promotion As Part Of Its Redesigned Website Launch
RVMDW

PR Newswire

6 months ago

Jamaica Villas Offers "Free Driver" Promotion As Part Of Its Redesigned Website Launch

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
RVMDW

CNW Group

6 months ago

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
RVMDW

GlobeNewswire

6 months ago

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
RVMDW

GlobeNewswire

6 months ago

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
RVMDW

GlobeNewswire

6 months ago

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
RVMDW

GlobeNewswire

6 months ago

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

RVMDW

MT Newswires

7 months ago

Revolution Medicines Insider Sold Shares Worth $299,942, According to a Recent SEC Filing

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
RVMDW

GlobeNewswire

7 months ago

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

Revolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...
RVMDW

GuruFocus.com

7 months ago

Revolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...

Revolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)
RVMDW

Simply Wall St.

7 months ago

Revolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)

Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript
RVMDW

Insider Monkey

7 months ago

Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript

RVMDW

MT Newswires

7 months ago

Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating

RVMDW

GuruFocus.com

7 months ago

Revolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

RVMDW

MT Newswires

7 months ago

Revolution Medicines Q1 Net Loss Narrows

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
RVMDW

GlobeNewswire

7 months ago

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

Insider Sale: CFO Jack Anders Sells 10,000 Shares of Revolution Medicines Inc (RVMD)
RVMDW

GuruFocus.com

8 months ago

Insider Sale: CFO Jack Anders Sells 10,000 Shares of Revolution Medicines Inc (RVMD)

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
RVMDW

GlobeNewswire

8 months ago

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMDW

GlobeNewswire

8 months ago

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMDW

GlobeNewswire

8 months ago

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Revolution Medicines to Participate in Upcoming Investor Conferences
RVMDW

GlobeNewswire

9 months ago

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
RVMDW

GlobeNewswire

9 months ago

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript
RVMDW

Insider Monkey

10 months ago

Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript

Revolution Medicines Full Year 2023 Earnings: Misses Expectations
RVMDW

Simply Wall St.

10 months ago

Revolution Medicines Full Year 2023 Earnings: Misses Expectations

RVMDW

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Revolution Medicines Inc Earnings Call

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
RVMDW

Zacks

10 months ago

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates

Revolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical Progress
RVMDW

GuruFocus.com

10 months ago

Revolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical Progress

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
RVMDW

GlobeNewswire

10 months ago

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
RVMDW

GlobeNewswire

10 months ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout
RVMDW

Zacks

a year ago

Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout

Revolution Medicines to Participate in Upcoming Investor Conferences
RVMDW

GlobeNewswire

a year ago

Revolution Medicines to Participate in Upcoming Investor Conferences

Chapel Hart Kicks Off Ford Truck Month with "This Girl Likes Fords"
RVMDW

Business Wire

a year ago

Chapel Hart Kicks Off Ford Truck Month with "This Girl Likes Fords"

Are You Looking for a High-Growth Dividend Stock?
RVMDW

Zacks

a year ago

Are You Looking for a High-Growth Dividend Stock?

E2IP strengthens its Board of Directors for accelerated global scalability. Accomplished CEO and Fortune 500 Executive, Michael J. Loparco, joins E2IP Board of Directors
RVMDW

PR Newswire

a year ago

E2IP strengthens its Board of Directors for accelerated global scalability. Accomplished CEO and Fortune 500 Executive, Michael J. Loparco, joins E2IP Board of Directors

HS2 bosses in talks to scrap first-class seats to maintain passenger capacity
RVMDW

The Telegraph

a year ago

HS2 bosses in talks to scrap first-class seats to maintain passenger capacity

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
RVMDW

Motley Fool

a year ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

RVMDW

Associated Press Finance

a year ago

First Merchants: Q4 Earnings Snapshot

First Merchants Corporation Announces Fourth Quarter 2023 Earnings Per Share
RVMDW

GlobeNewswire

a year ago

First Merchants Corporation Announces Fourth Quarter 2023 Earnings Per Share

Meta Materials Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
RVMDW

ACCESSWIRE

a year ago

Meta Materials Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
RVMDW

Zacks

a year ago

Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?

RVMDW

GlobeNewswire

a year ago

WinVest Acquisition Corp. Announces Extension of Termination Date and Additional Contribution to Trust Account to Extend Termination Date

Share on Social Networks: